Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar and/or nedaplatin intrapleural perfusion for malignant pleural effusion
ChiCTR1800016259Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of endostar and nedaplatin in malignant pleural effusion (MPE) (3 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Started Jun 2018; status: recruiting.
02
Drugs
endostarnedaplatin
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on ChiCTR1800016259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016259.